Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20535618 | 1.00 | APLNR (0.35) | APLNRDGAT1CYP2D6HDAC3HDAC1 | |
| SCHEMBL25182441 | 1.00 | APLNR (0.35) | APLNRDGAT1CYP2D6HDAC3HDAC1 | |
| SCHEMBL20535616 | 1.00 | APLNR (0.35) | APLNRDGAT1CYP2D6HDAC3HDAC1 | |
| SCHEMBL13907508 | 0.98 | APLNR (0.36) | APLNRDGAT1CYP2D6HDAC3HDAC1 | |
| SCHEMBL20535026 | 0.92 | CES2 (0.39) | APLNRCYP2D6TDP1CA12CA2 | |
| SCHEMBL23405409 | 0.92 | CES2 (0.43) | APLNRHDAC1HDAC2HDAC6TDP1 | |
| SCHEMBL21876660 | 0.92 | DGAT1 (0.33) | APLNRDGAT1CYP2D6CA12CA2 | |
| SCHEMBL23451362 | 0.92 | DGAT1 (0.33) | APLNRDGAT1CYP2D6CA12CA2 | |
| SCHEMBL20534803 | 0.92 | VCAM1 (0.33) | APLNRCYP2D6SMN1; SMN2HSD17B10 | |
| SCHEMBL21348710 | 0.92 | ALDH1A1 (0.42) | APLNRCYP2D6CES2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312639-A1 | GPER PROTEOLYTIC TARGETING CHIMERAS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2023-10-05 | — | — | US | disclosed |
| US-20230312639-A1 | GPER PROTEOLYTIC TARGETING CHIMERAS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2023-10-05 | — | — | US | disclosed |
| US-20230312639-A1 | GPER PROTEOLYTIC TARGETING CHIMERAS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2023-10-05 | — | — | US | disclosed |
| CN-115835886-A | GPER proteolytic targeting chimeras | 衣阿华大学研究基金会 | 2023-03-21 | — | — | CN | disclosed |
| EP-4138921-A1 | GPER PROTEOLYTIC TARGETING CHIMERAS | University Of Iowa Research Foundation (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220127257-A1 | SMALL MOLECULES | UNIVERSITY OF DUNDEE (GB) | 2022-04-28 | — | — | US | disclosed |
| US-11261179-B2 | Small molecules | UNIVERSITY OF DUNDEE (GB) | 2022-03-01 | — | — | US | disclosed |
| WO-2021217036-A1 | GPER PROTEOLYTIC TARGETING CHIMERAS | SALEM ALIASGER K (US) | 2021-10-28 | — | — | WO | disclosed |
| US-20210163469-A1 | SMALL MOLECULES | UNIVERSITY OF DUNDEE (GB) | 2021-06-03 | — | — | US | disclosed |
| EP-3609889-A1 | SMALL MOLECULES | University Of Dundee (GB) | 2020-02-19 | — | — | EP | disclosed |
| CN-110573507-A | small molecules | 邓迪大学 | 2019-12-13 | — | — | CN | disclosed |
| WO-2019078522-A1 | CEREBLON PROTEIN DEGRADATION INDUCING COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2019-04-25 | — | — | WO | disclosed |
| WO-2018189554-A1 | SMALL MOLECULES | UNIVERSITY OF DUNDEE (GB) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312639-A1 | GPER PROTEOLYTIC TARGETING CHIMERAS | GPER1, ESR1, ADRM1 | APLNR 179/4885DGAT1 2938/4885CYP2D6 1606/4885 |
| US-20220127257-A1 | SMALL MOLECULES | ADRM1, MDM2, UBE2B | APLNR 3086/4885DGAT1 4569/4885CYP2D6 2033/4885 |
| US-11261179-B2 | Small molecules | ADRM1, MDM2, UBE2B | APLNR 3086/4885DGAT1 4569/4885CYP2D6 2033/4885 |
| US-20210163469-A1 | SMALL MOLECULES | ADRM1, MDM2, UBE2B | APLNR 3086/4885DGAT1 4569/4885CYP2D6 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.